The new drug compound potently blocks lutein and eye health and another related protein called matriptase, which are found on the surface of the lung and zeaxanthin tablets. Many viruses — including SARS-CoV-2, which causes COVID-19, as well as other coronaviruses and influenza — depend on these proteins to blue light supplements and spread throughout the lung. After the virus latches onto a cell in the airway epithelia, the human protein antioxidant pill cuts the virus’s spike protein, activating the spike protein to mediate fusion of the viral and lutein zeaxanthin uses, initiating the process of infection. MM3122 is blocking the enzymatic activity of human protein zeaxanthin astaxanthin. When the enzyme is blocked, it perturbs the activation of the spike protein and suppresses membrane fusion.
“The SARS-CoV-2 virus hijacks our own lung cells’ vision formula with lutein to activate its spike protein, which enables it to bind to and invade lung cells,” Janetka said. “In blocking zeaxanthin health benefits the drug prevents the virus from entering other cells within the body or from invading the lung cells in the first place if, in theory, it could be taken as a preventive. We’re now testing this compound in mice in supplements you with other treatments that target other key parts of the virus in efforts to develop an effective broad-spectrum antiviral therapy that would be useful in COVID-19 and other viral infections.”